1114 related articles for article (PubMed ID: 29561981)
41. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
[TBL] [Abstract][Full Text] [Related]
42. Noninvasive characterization of graft steatosis after liver transplantation.
Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
[TBL] [Abstract][Full Text] [Related]
43. Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP).
Papapostoli I; Lammert F; Stokes CS
J Gastrointestin Liver Dis; 2016 Jun; 25(2):175-81. PubMed ID: 27308648
[TBL] [Abstract][Full Text] [Related]
44. Hepatic steatosis in obese Chinese children.
Chan DF; Li AM; Chu WC; Chan MH; Wong EM; Liu EK; Chan IH; Yin J; Lam CW; Fok TF; Nelson EA
Int J Obes Relat Metab Disord; 2004 Oct; 28(10):1257-63. PubMed ID: 15278103
[TBL] [Abstract][Full Text] [Related]
45. Controlled attenuation parameter for the detection of hepatic steatosis in patients with chronic hepatitis B.
Chen J; Wu D; Wang M; Chen E; Bai L; Liu C; Liao J; Tang H
Infect Dis (Lond); 2016 Sep; 48(9):670-5. PubMed ID: 27241724
[TBL] [Abstract][Full Text] [Related]
46. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
[TBL] [Abstract][Full Text] [Related]
47. How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?
Trowell J; Alukal J; Zhang T; Liu L; Maheshwari A; Yoo HY; Thuluvath PJ
Dig Dis Sci; 2021 Apr; 66(4):1297-1305. PubMed ID: 32337667
[TBL] [Abstract][Full Text] [Related]
48. The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort.
Cardoso AC; Cravo C; Calçado FL; Rezende G; Campos CFF; Neto JMA; Luz RP; Soares JAS; Moraes-Coelho HS; Leite NC; Perez RM; Villela-Nogueira CA
Eur J Gastroenterol Hepatol; 2020 Feb; 32(2):231-238. PubMed ID: 31464788
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter.
Kaya E; Demir D; Alahdab YO; Yilmaz Y
Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1264-7. PubMed ID: 27482784
[TBL] [Abstract][Full Text] [Related]
50. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
Lefere S; Dupont E; De Guchtenaere A; Van Biervliet S; Vande Velde S; Verhelst X; Devisscher L; Van Vlierberghe H; Geerts A; De Bruyne R
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2317-2326.e4. PubMed ID: 34871812
[TBL] [Abstract][Full Text] [Related]
51. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.
Baumeler S; Jochum W; Neuweiler J; Bergamin I; Semela D
Swiss Med Wkly; 2019 Apr; 149():w20077. PubMed ID: 31026041
[TBL] [Abstract][Full Text] [Related]
52. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity.
Ooi GJ; Earnest A; Kemp WW; Burton PR; Laurie C; Majeed A; Johnson N; McLean C; Roberts SK; Brown WA
Int J Obes (Lond); 2018 Nov; 42(11):1900-1911. PubMed ID: 29463916
[TBL] [Abstract][Full Text] [Related]
53. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
Lee YH; Kim KJ; Yoo ME; Kim G; Yoon HJ; Jo K; Youn JC; Yun M; Park JY; Shim CY; Lee BW; Kang SM; Ha JW; Cha BS; Kang ES
J Hepatol; 2018 Apr; 68(4):764-772. PubMed ID: 29175242
[TBL] [Abstract][Full Text] [Related]
54. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy.
Yilmaz Y; Yesil A; Gerin F; Ergelen R; Akin H; Celikel ÇA; Imeryuz N
Scand J Gastroenterol; 2014 May; 49(5):611-6. PubMed ID: 24611771
[TBL] [Abstract][Full Text] [Related]
55. [A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver].
Shen F; Zheng R; Mi Y; Shi J; Chen G; Chen J; Xu L; Pan Q; Xu L; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2014 Dec; 22(12):926-31. PubMed ID: 25654287
[TBL] [Abstract][Full Text] [Related]
56. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults.
Guo W; Lu J; Qin P; Li X; Zhu W; Wu J; Xu N; Zhang Q
Lipids Health Dis; 2020 Oct; 19(1):218. PubMed ID: 33028338
[TBL] [Abstract][Full Text] [Related]
57. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.
Xu L; Lu W; Li P; Shen F; Mi YQ; Fan JG
Dig Liver Dis; 2017 Aug; 49(8):910-917. PubMed ID: 28433586
[TBL] [Abstract][Full Text] [Related]
58. Transient elastography and controlled attenuation parameter to evaluate hepatic steatosis and liver stiffness in postpartum patients.
Hussain FN; Rosenbluth E; Feldman KM; Strauss TS; Schneider E; Schmidt-Beauchat E; Rodriguez-Rivas C; Brustman L; Kushner T
J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2190838. PubMed ID: 36935368
[TBL] [Abstract][Full Text] [Related]
59. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
[TBL] [Abstract][Full Text] [Related]
60. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
